Advances in the first line treatment of pancreatic cancer

Advances in the first line treatment of pancreatic cancer

oncologyeducation

5 years
4,295 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Results of the MPACT Trial (weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone) in patients with metastatic pancreatic cancer will be reviewed, with emphasis on patient selection and neuropathy management. The webinar was delivered by Dr. Malcolm Moore, Program Head, Medical Oncology and Hematology, Director, McCain Centre for Pancreatic Cancer; Professor, Department of Medicine and Pharmacology, University of Toronto.
Up Next Autoplay